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Using Tandem Mass Spectrometry for Metabolic
Disease Screening Among Newborns
A Report of a Work Group
“Public health agencies (federal and state), in partnership with
health professionals and consumers, should continue to develop and
evaluate innovative testing technologies [and] design and apply
minimum standards for newborn screening activities . . . .”
Newborn Screening Task Force, May 1999
Summary
Increasingly, tandem mass spectrometry (MS/MS) is being used for newborn
screening because this laboratory testing technology substantially increases the
number of metabolic disorders that can be detected from dried blood-spot
specimens. In June 2000, the National Newborn Screening and Genetics
Resource Center, in collaboration with CDC and the Health Resources and
Services Administration, convened a workshop in San Antonio, Texas. Workshop
participants examined programmatic concerns for health providers choosing to
integrate MS/MS technology into their newborn screening activities. Representa-
tives from approximately 50 public and private health agencies and universities
participated in the workshop. The workshop participants and work group focused
on laboratory methodology, decision criteria, quality assurance, diagnostic
protocols, patient case management, and program evaluation for using MS/MS to
analyze dried blood spots routinely collected from newborns. This work group
report contains proposals for planning, operating, and evaluating MS/MS
technology in newborn screening and maternal and child health programs. As a
supplement to these proposals, this report contains synopses of selected
presentations made at the 2000 workshop regarding integration of MS/MS
technology into newborn screening programs. The proposals contained in this
report should assist policymakers, program managers, and laboratorians in
making informed decisions regarding the process of including MS/MS technology
in their newborn screening and maternal and child health programs.
INTRODUCTION
Each year, approximately 4 million babies in the United States have dried blood spots
analyzed through newborn* screening programs. This screening is intended to detect
inborn disorders that can result in early mortality or lifelong disability. Detectable disor-
ders include metabolic disorders (e.g., phenylketonuria [PKU]), hematologic disorders
(e.g., sickle cell disease), and endocrinopathies (e.g., congenital hypothyroidism). These
three groups of disorders account for approximately 3,000 new cases of potentially fatal
* Newborn is defined as an infant aged <1month.
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or debilitating disease each year for which outcomes are improved with early identifica-
tion and treatment through newborn screening systems. The introduction of tandem
mass spectrometry (MS/MS) in the 1990s for population-based newborn screening has
enabled health-care providers to detect an increased number of metabolic disorders in a
single process by using dried blood-spot specimens routinely collected from newborns
(1–3 ). However, using MS/MS in newborn screening programs is new, and scientific data
are limited regarding incorporating this technology into newborn screening and mater-
nal and child health programs.
MS/MS technology enables improvements in and consolidation of metabolic screen-
ing methods to detect amino acid disorders (e.g., PKU, maple syrup urine disease, and
homocystinuria) among newborns, and does so with a low false-positive rate (4–6 ). MS/
MS technology expands the metabolic disorder screening panel (i.e., the number of
disorders that can be detected) by incorporating an acylcarnitine profile, which enables
detection of fatty acid oxidation disorders (e.g., medium-chain acyl-CoA dehydrogenase
[MCAD] deficiency) (7–10 ) and other organic acid disorders. MS/MS can reliably analyze
approximately 20 metabolites in one short-duration run (i.e., ~2 minutes) and provide a
comprehensive assessment from a single blood-spot specimen (Table 1).
Screening for multiple disorders in a single analytical run by using MS/MS requires
that program administrators and laboratorians choose which types of conditions are to
be screened. For example, laboratory A uses MS/MS to detect amino acids only; labora-
tory B uses MS/MS to detect acylcarnitines only; and laboratory C screens for both. In
addition, other technical concerns must be addressed before MS/MS technology can be
integrated effectively into a newborn screening program, including deciding which
analytes to use in characterizing each disorder (e.g., octanoylcarnitine analysis can indi-
cate both MCAD deficiency and multiple acyl-CoA dehydrogenase deficiency).
Studies are limited regarding use of MS/MS technology in newborn screening pro-
grams, but existing studies indicate that screening a full panel of acylcarnitines and
amino acids yields rates of 1:4,000–1:5,000 for MS/MS-detectable disorders (11–13 ). For
certain metabolic disorders, early detection can result in substantial improvements in
health outcomes. For example, MCAD, which has an incidence rate of 1:10,000–1:20,000
newborns, results in substantial morbidity and reported mortality rates of 20%–25%
among infants and children during the first 3 years of life (14 ). Effective treatment is
available, and detection and intervention before onset of illness can prevent mortality
and improve the quality of life for MCAD patients. Although effective treatments do not
exist yet for certain other metabolic disorders identifiable by MS/MS testing (1 ), patient
and family advantages can still be achieved through early diagnosis (15 ). Also, MS/MS
can detect metabolic disorders after an illness occurs, even if that illness occurs after the
newborn period (Table 2).
June 2000 Workshop and Work Group Goals
In June 2000, the National Newborn Screening and Genetics Resource Center, in
collaboration with CDC and the Health Resources and Services Administration (HRSA),
convened a workshop in San Antonio, Texas, to examine programmatic concerns for
effectively integrating MS/MS technology into newborn screening programs. Represen-
tatives from approximately 50 public and private health agencies and universities par-
ticipated in the workshop.* The participants focused on laboratory methodology, decision
* The proposals in this report are based on conclusions derived by participants in the plenary
and work group sessions held during the workshop.
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TABLE 1. Metabolic disorders detectable in newborns aged 1–5 days by using tandem
mass spectrometry
Disorder Primary metabolic indicator
Amino Acids
Phenylketonuria Phe
Maple syrup urine disease Leu/Ile, Val
Homocystinuria (cystathione synthase deficiency) Met
Hypermethioninemia Met
Citrullinemia Cit
Argininosuccinic aciduria Cit
Tyrosinemia, type I Tyr
Fatty Acids
Medium-chain acyl-CoA dehydrogenase deficiency C8, C10, C10:1, C6
Very-long–chain acyl-CoA dehydrogenase deficiency C14:1, C14, C16
Short-chain acyl-CoA dehydrogenase deficiency C4
Multiple acyl-CoA dehydrogenase deficiency C4, C5, C8:1, C8, C12, C14, C16, C5DC
Carnitine palmitoyl transferase deficiency C16, C18:1, C18
Carnitine/acylcarnitine translocase defect C16, C18:1, C18
Long-chain hydroxy acyl-CoA dehydrogenase deficiency C16OH, C18:1OH, C18OH
Trifunctional protein deficiency C16OH, C18:1OH, C18OH
Organic Acids
Glutaric acidemia, type I C5DC
Propionic acidemia C3
Methylmalonic acidemia C3
Isovaleric acidemia C5
3-hydroxy-3-methylglutaryl CoA lyase deficiency C5OH
3-methylcrotonyl CoA carboxylase deficiency C5OH
Notes: The list of primary metabolic indicators is not all-inclusive and serves only as a guideline. It is based on
results obtained from laboratories experienced in tandem mass spectrometry technology and that serve as diagnos-
tic metabolic laboratories in the United States and other countries. The identified disorders have been detected from
analyses of dried blood-spot specimens collected during the newborn period. Certain disorders require complex
metabolic profiles and intermetabolic relation to detect disease with low false-positive and no false-negative rates.
criteria, quality assurance, diagnostic protocols, patient case management, and pro-
gram evaluation. This report contains their proposals for planning, operating, and evalu-
ating MS/MS technology in newborn screening and maternal and child health programs.
Their proposals are included in this report to assist policymakers, program managers,
and laboratorians in planning state-mandated screening programs or optional metabolic
testing through partnering of state and private screening laboratories. The workshop
participants did not address newborn disorders that are screened by other technologies
and that should be considered for a comprehensive newborn screening panel (e.g.,
sickle cell disease, congenital adrenal hyperplasia, galactosemia, biotinidase deficiency,
and cystic fibrosis). Therefore, these proposals address MS/MS technology only. Fur-
ther, as a supplement to their proposals, this report contains synopses of selected pre-
sentations made at the 2000 workshop regarding integration of MS/MS technology into
newborn screening programs (Appendix).
Specifically, workshop participants focused on the following concerns for
policymakers, program managers, and laboratorians interested in MS/MS testing for
newborn screening programs:
• What barriers exist that impede MS/MS implementation?
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• What technical concerns exist regarding instrumentation (e.g., throughput, cost,
software, accessories, or capabilities)?
• What are the approaches and cutoff decisions for identifying presumptive
positive test results?
• What guidance do program managers and laboratorians need who are planning
to use, are using already, or are evaluating MS/MS technology for newborn
screening?
• What are the expectations and resource needs for follow-up, diagnostic
confirmation, parental genetic counseling, and patient case management?
• What are the medical concerns for parents and health-care providers, including
identification and treatment of MS/MS-diagnosed disorders?
• How would program evaluation be conducted for MS/MS integration, including
quality control and proficiency testing?
In their discussions, workshop participants considered the role parent support groups*
and advocacy organizations are taking in promoting inclusion of MS/MS technology in
newborn screening services. This increased advocacy has resulted in increased media
attention regarding the health burden of metabolic disorders among newborns (16,17 ).
Consequently, more newborn screening program administrators and maternal and child
health-care providers are considering integrating this technology into their programs
(18 ). Key factors in deciding to implement MS/MS are its versatility and ability to detect
additional treatable metabolic diseases, including fatty acid and organic acid oxidation
disorders. However, medical literature is limited regarding use of MS/MS technology in
newborn screening programs. Furthermore, the identification of metabolic disorders
* Example parent support groups are located at the following Internet sites:
<http://www.pku-allieddisorders.org> (accessed March 12, 2001).
<http://www.tylerforlife.com> (accessed March 12, 2001).
TABLE 2. Metabolic disorders detectable in patients aged >5 days by using tandem mass
spectrometry
Disorder Primary metabolic indicator
Argininemia Arg
Nonketotic hyperglycinemia Gly
Tyrosinemia, type II Tyr
Hyperammonemia, hyperornithinemia,
homocitrullinuria syndrome Orn, HomoCit
5-oxoprolinuria 5-Oxopro
Carnitine palmitoyl transferase, type I deficiency Free CN
Isobutyrl CoA dehydrogenase deficiency C4
Mitochondrial acetoacetyl CoA thiolase deficiency C5:1,C5OH
Malonic aciduria C3-DC
2-methylbutyrl CoA dehydrogenase deficiency C5
Notes: The list of primary metabolic indicators is not all-inclusive and serves only as a guideline. The identified
disorders have been detected by tandem mass spectrometry as a result of follow-up testing conducted because of
illness or for older children with suspected underlying metabolic disorders. Disorders listed might not be detectable
during the newborn period. Many disorders require complex metabolic profiles and intermetabolic relation to detect
disease with low false-positive and no false-negative rates.
Vol. 50 / No. RR-3 MMWR 5
must be confirmed by validated scientific methodologies. Additional studies are needed
to assess effectiveness of MS/MS, and sustained discussions among those persons
involved in using or contemplating using MS/MS should be ongoing to enable
policymakers, program managers, and laboratorians to make more informed decisions.
BACKGROUND
In the 1930s, amino acid metabolism disorders and in the 1970s, fatty acid oxidation
disorders were recognized as causes of morbidity and mortality among infants and
children. As metabolic disorders were recognized, researchers worked to develop
methods to detect them. In the 1960s, population screening for amino acid disorders
began, and in the mid-1980s, one researcher demonstrated the therapeutic value of
measuring the fatty acids released from acylcarnitines (19 ). Early analytical methods
required hydrolysis of fatty acids from acylcarnitines or analysis of urinary organic acid
profiles as primary analytical approaches to diagnosing inborn errors of metabolism
(20,21 ). Acylcarnitines are quaternary ammonium salts that are not readily analyzed by
gas chromatography/mass spectrometry, a readily available clinical chemistry method.
With the introduction of fast-atom–bombardment ionization techniques for MS, ionic
compounds with high polarity (e.g., acylcarnitines) could be analyzed with simple prepa-
ration techniques (22 ). Use of MS/MS for acylcarnitine analytes in plasma eliminated
time-consuming chromatography but maintained method specificity (23,24 ). Rapid analy-
ses of highly polar compounds made possible use of MS/MS in newborn screening, which
requires rapid high throughput to be cost-effective. Also, during the 1980s, improved
diagnostic skills enabled better recognition of disorders of intermediary metabolism. In
1990, analyses of amino acids present in dried blood-spot specimens were used to docu-
ment newborn screening applications of MS/MS (4,5,10,25 ). Existing methodology for
the MS/MS analyses of acylcarnitines was modified and combined with that for amino
acids in an approach that remains relatively unchanged.
During the early 1990s, improvements were made in automated analysis, in part
enabled by the introduction of electrospray ionization, sample-introduction techniques,
method validation, and development of automated interpretation systems (8,9,11,12,26–
29 ). Concurrently, the number of specimens analyzed annually increased substantially.
From the first analyses in 1990 of 5–10 specimens/day in clinical testing laboratories to
early pilot studies in 1993 of 60–120 specimens/day (11 ), the use of MS/MS technology
has grown exponentially so that, during 2000, an estimated 500,000 specimens* were
analyzed (Figure 1).
With increased demand for expanded newborn screening, MS/MS technology has
been successfully implemented in private sector and public health laboratories across
the United States (Figure 2). Routine, state-sponsored screening using MS/MS is per-
formed in the District of Columbia, New England (i.e., Massachusetts, New Hampshire,
Vermont, Maine, Rhode Island), North Carolina, and Wisconsin. However, the technology
is used for screening acylcarnitine profiles in only three of these states: Massachusetts,
North Carolina, and Wisconsin. In addition, optional supplemental testing (i.e., testing for
diseases not included in the selected panel of a state screening program) is offered for a
*This estimate is a summation of the known birth rate for the states where MS/MS technology
was used for newborn screening in 2000.
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fee by Neo Gen Screening, Inc.* (Bridgeville, Pennsylvania) and the Institute of Metabolic
Disease† (Baylor University Medical Center, Dallas, Texas) to parents, physicians, and
hospitals either directly or through state newborn screening programs. Pilot testing is
under way in Illinois, Iowa, Louisiana, and Ohio; and California, Minnesota, and New York
have purchased MS/MS equipment.
LABORATORY PRACTICE
Policymakers and program managers need to be familiar with standards for MS/MS
testing when soliciting, contracting, or evaluating newborn screening laboratory ser-
vices. Work group proposals regarding implementation and operation of MS/MS labora-
tories are provided here with the understanding that this technology is new and, therefore,
changing rapidly. Although modifications throughout the testing system are to be
expected, all changes in laboratory practice should adhere to published laboratory guide-
lines before being implemented.
Nomenclature
Basic knowledge of MS/MS technology standards and laboratory practice requires an
understanding of the scientific terminology.
*Additional information is available at <http://www.neogenscreening.com> (accessed January
17, 2001).
†Additional information is available at <http://www.baylordallas.edu/newbornscreening>
(accessed February 16, 2001).
FIGURE 1. Progress leading to the introduction of tandem mass spectrometry (MS/MS)
in newborn screening
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Work Group Proposals
• The technology should be referred to as tandem mass spectrometry, not tandem
mass spectroscopy.
• The standard abbreviation for tandem mass spectrometry is MS/MS, not TMS  or
TM/TM. MS/MS  represents two mass spectrometers joined by a fragmentation
chamber.
• A universal description of the analytes and disease states is needed. For example,
succinate  and methylmalonate  can refer to the same analyte. MCAD  and
MCADD  are used interchangeably to refer to medium-chain acyl-CoA
dehydrogenase deficiency. A task force of laboratorians and clinical specialists
should work to resolve such nomenclature differences.
• Acylcarnitine results should be reported in micromolar (µM) units (whole blood),
and amino acids should be reported as micromolar (µM) (whole blood) with the
concentration in milligrams per deciliter (mg/dL) given in parentheses.
FIGURE 2. Tandem mass spectrometry (MS/MS) integration into newborn screening
programs — United States, December 2000
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Standard and Sample Preparation
Work Group Proposals
• Sample preparation techniques for acylcarnitines and amino acids should be
validated in accordance with the Clinical Laboratory Improvement Amendments
of 1988 (30 ) and good laboratory* and measurement† practices (31 ).
• All reagents, buffers, and solvents should be high-pressure liquid chromatogra-
phy grade or better.
• Validated methods should be published in peer-reviewed journals.
• When stable-isotope internal-standard methodology is used, the labeled internal
standard should be identical to the analyte of interest. If the analyte is not
available in the labeled form, the nearest homologue can be substituted. For
example, the diagnostic analyte is phenylalanine for PKU, which requires
D5-phenylalanine, or equivalent, for quantitation. However, not all acylcarnitines
will be available as internal standards for detecting fatty acid oxidation or organic
acid oxidation disorders by measuring acylcarnitines levels. Therefore, for a
complete acylcarnitine profile, D9-C0, D3-C3, D3-C4, D9-C5, D3-C14, and D3-C16
should be used as internal standards. Other isotopes can be used if they are
properly validated. Limited profiling might involve fewer internal standards but
still requires validation.
• Individual and premixed stable-isotope internal standards are commercially
available. Commercial suppliers should include a statement regarding the
standard material’s concentration and stability. Dilutions of commercial
standards or in-house preparations should be validated by analyzing unlabeled
materials (i.e., controls) before use.
• Stability of internal-standard or quality-control preparations should be validated
and documented for each laboratory performing MS/MS analyses.
• Testing protocols should specify what safety recommendations, universal
precautions, personal protective gear, and environmental controls are required.
• Sample preparation areas should be physically separated from instrument areas
to avoid contamination. One MS/MS instrument should have a capacity of
500 samples/day. Good laboratory and measurement practices should be
followed (31 ).
* Good laboratory practice is defined as an acceptable way to perform a basic activity that is
known to influence the quality of its output.
†Good measurement practice is defined as an acceptable way to perform an operation with
a specific measurement technique known to influence the quality of the measurement.
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Instrument Resources and Calibration
Work Group Proposals
• Manufacturer’s guidelines for power requirements, exhaust specifications,
laboratory gas purity and pressure, and laboratory environment should be
followed. All MS/MS used for metabolic disease detection requires high-purity
compressed nitrogen delivered at a specified pressure. This gas can be supplied
by nitrogen generators, compressed gas tanks, or Dewar tanks. Certain
instruments require uninterrupted gas flow; therefore, the ability to change tanks
regularly without interruption of flow or loss of pressure is required (i.e., empty
tanks connected to the system must be replaced with filled tanks before all tanks
become empty).
• Additional peripheral equipment for MS/MS is required, including a liquid
chromatography pump, syringe pump for calibrating and tuning, and an
autosampler (preferably one capable of holding multiple 96-well microplates).
Sample preparation equipment might include sample concentrators, forced air
ovens or equivalent, and reagent-dispensing devices (either automated or hand-
held). Nearby telephone access is desirable for instrument troubleshooting.
• Operators of MS/MS instruments should hold a minimum of a bachelor of science
degree in a laboratory science or medical technology. In addition, they must meet
the pertinent Clinical Laboratory Improvement Amendments of 1988 personnel
requirements (30 ). Additionally, MS/MS laboratorians should have a) mechanical
aptitude, b) computer skills, and c) an interest in mass spectrometry technology.
Each instrument requires one primary laboratorian and a backup. Laboratories
having multiple instruments should have an equal number of personnel plus one
or two laboratorians, depending on whether the supervisor serves as the backup.
• Managers and supervisors of MS/MS operations should have background
experience in mass spectrometry. One manager is sufficient to oversee multiple
instruments.
• Newborn screening laboratories should develop a backup plan for instrument
downtime. That plan should include ready access to additional instruments or
backup laboratories.
• Each instrument manufacturer’s recommended calibration procedure should be
followed. These procedures involve using a standard material (e.g., sodium
iodide, rubidium iodide, polypropylene glycol, or similar compound).
• Mass scales should be calibrated above and below the mass range of interest.
Calibration from 23 megahertz to 600 megahertz should suffice for analyses being
performed in metabolic disease investigations.
• Users should prepare an instrument check solution at a defined concentration
comparable to patient specimens in mass and intensity. This solution should be
used daily to measure the sensitivity of the instrument. Results, as counts or
signal intensities, should be recorded each day and a minimum signal intensity
established as an alert of a possible change in instrument performance. Check
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solutions should contain the same mix of standards used to calibrate the assay. A
higher concentration tuning solution should be available also and separate from
the routine check solution. This tuning solution enables optimization of
parameters for individual acylcarnitines that might have variable ionization
efficiencies of short- versus long-chain acylcarnitines and neutral versus basic
amino acids.
Reducing Instrument-to-Instrument Variability
Work Group Proposals
• Because quantitative results for raw ion counts can vary from instrument to
instrument, a minimum sensitivity threshold for all instruments should be defined
before use. Concentration calculations using ion ratios (i.e., the mass of unlabeled
analyte versus labeled internal standards) should vary <10% from instrument to
instrument. NCCLS* voluntary consensus definitions of quantitation and
detection limits should be used (32 ).
• When the concentration of an analyte is close to the detection limits of the method,
as for certain acylcarnitines, differences between apparent normal results from
one instrument to another can result from electronic signal noise. This difference
should decrease as a particular analyte level increases and should be minimal in
true disease states when multiple instruments are properly maintained.
Quality Control, Proficiency Testing, and Quality Assurance
Work Group Proposals
• Quality control should consist of >2 control specimens/96-well microplate. One
control should contain analyte concentrations above the abnormal reporting
level, and the second control should be at or near the abnormal cutoff value. The
fatty acid oxidation disorder and organic aciduria disorder controls should contain
as many of the acylcarnitines as are commercially available.
• A reagent blank should be included on each plate and should be located after the
high-level control to monitor analytical carry-over.
• The daily patient mean, or median, for each analyte should be monitored to follow
method performance.
• A schedule for routine maintenance should be established for quality
performance. Maintenance schedules should follow manufacturers’ recommen-
dations and each instrument’s operational experience.
* Formerly the National Committee for Clinical Laboratory Standards.
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• External quality-control specimens should be analyzed periodically. CDC’s
Newborn Screening Quality Assurance Program, operated in collaboration with
the Association of Public Health Laboratories, can provide control materials for
amino acids and acylcarnitines.* For acylcarnitines, the calculated concentrations
are dependent on the internal standard to which the unlabeled acylcarnitine is
compared. Therefore, when interlaboratory comparisons are performed, the
internal standards used to calculate the reported values need to be defined. Using
a relative response factor by dividing each laboratory’s observed value by the
expected value might be advantageous when interlaboratory performances are
compared.
• A government-supported external proficiency testing program is needed for
newborn screening laboratories using MS/MS testing (1 ). CDC’s Newborn
Screening Quality Assurance Program is pursuing addition of a dried blood-spot
proficiency testing program for MS/MS-detectable disorders. Proficiency testing
challenges should include quantitation of analytes and assessment of the
laboratory’s capability to recognize disease profiles. CDC’s program is producing
dried blood-spot materials for amino acids and acylcarnitines quality control and
proficiency testing purposes, but problems remain with standardization of such
analytes as glutarylcarnitine and hydroxyacylcarnitines for which no synthetic
material is available. When external proficiency testing is not available, an
interlaboratory specimen exchange program with documented results should be
established to assess accuracy in detecting metabolic disease profiles.
• Results of a newborn screening test might be affected by the patient’s medical
treatment before specimen collection. Research is needed regarding the effect of
carnitine-fortified total parenteral nutrition and hyperalimentation solutions,
transfusions, prescription drugs, and metabolites that can affect the MS/MS test
results. Discrepancies among multiple sample collections should be discussed
with metabolic specialists, physicians, and the patient’s primary care provider.
• MS/MS, although specific and accurate, is one of multiple tests performed in
newborn screening laboratories. As with other tests, abnormal results should be
confirmed by additional diagnostic testing, including MS/MS serum analysis, gas
chromatography/mass spectrometry urinary organic acid analysis, or quantita-
tive high-pressure liquid chromatography using ion exchange or similar
approaches, depending on disease confirmation.
• An electronic communication system (e.g., an on-line bulletin board service)
should be used for information exchange among laboratories regarding MS/MS
operational issues, problems, and solutions.†
* Additional information is available at <http://www.cdc.gov/nceh/dls/newborn_screening.htm>
(accessed March 12, 2001).
† Readers can subscribe to the following electronic bulletin board,
<MSMSWG@lists.uthscsa.edu>, by contacting Donna Williams at <williamsdc@uthscsa.edu>
and requesting a membership application.
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• The Association of Public Health Laboratories, in collaboration with other
organizations, should sponsor a regularly held workshop (e.g., annually) for
newborn screening MS/MS instrument users. In addition, a session regarding MS/
MS should be included at national and regional conferences on newborn
screening.
Interpreting MS/MS Data and Reporting Results
Work Group Proposals
• Cutoff values for reporting abnormal levels for each analyte should be
established by using statistical measurements (e.g., percentiles, means, and
standard deviations) in consultation with metabolic disease specialists. A multitier
system could be designed, depending on methodology, metabolic disorder, and
target population. Cutoff values should be compared with published ranges but
should be individualized to the methodology used and patient population. Cutoff
values should be adjusted up or down, on the basis of periodic re-evaluations or
changes in methodology or population distribution. Unless interinstrument
performance comparability is <10% (i.e., concentration calculations), instrument-
specific cutoff values should be developed. Programs with multiple instruments
should be able to perform satisfactorily for a single cutoff value.
• Laboratories can elect to establish two levels of abnormal results. One level
would be the concentration that is indicative of a particular disorder. Test results
greater than that concentration would require immediate referral to the clinical
management team for follow-up. The second level would be a borderline
concentration that would require resampling and retesting. Decisions to use this
two-level system might be dependent on the availability of follow-up resources.
• In addition to defining analyte concentrations or to profiling analytes, a ratio of
different analytes might be helpful in data interpretation. For example, the
phenylalanine/tyrosine ratios and C8/C10 acylcarnitine ratios might reduce false-
negatives and false-positives in PKU and MCAD detection, respectively.
• In addition to establishing a high cutoff value, setting a low cutoff value for certain
analytes would be useful. For example, a low, free carnitine might mask the
presence of a disorder (i.e., if low or undetectable carnitines are present,
acylcarnitines cannot be formed).
• For specimens collected from newborns aged >1 week, the acylcarnitine
measurements should be examined closely because acylcarnitines levels
decrease significantly with age. Establishing abnormal cutoffs for older babies is
an option, but could be difficult. Timing of specimen collection might be critical in
selected cases and result in invalid second specimens. Repeat testing of second
specimens collected from older newborns should not be considered a reliable
specimen for confirmation of all disorders.
• Reporting MS/MS results is the responsibility of each newborn screening
program. Screening laboratories should employ a trained, credentialed person to
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interpret screening profiles, similar to requirements for MS/MS diagnostic
laboratories. What results to report and how to report them should be decided in
consultation with state-designated referral centers, health-care practitioners, and
public health follow-up staff. Options include
— providing test data for both normal and abnormal results with or without
interpretation;
— providing only interpretation (i.e., test results are normal or abnormal); or
— combining these two options and reporting normal results as an interpretation
only (e.g., fatty acid oxidation is normal) and reporting abnormal results as
observed values with interpretations.
• Program managers should be aware that no U.S. Food and Drug Administration-
approved interpretive software for MS/MS newborn screening exists. Thus,
individual laboratory validation of interpretive protocols is required.
Specimen and Control Sample Storage
Work Group Proposals
• Stored patient specimens and control samples must be kept frozen at <–20 C with
humidity <30% to ensure long-term storage validity. Desiccants should be used to
maintain humidity levels. Laboratories should maintain written policies and
procedures that specify storage standards for specimens (1 ).
• When patients’ specimens are analyzed after storage, control samples stored
under the same conditions should also be used. Results of analyzing stored
specimens should be interpreted cautiously because long-term validation studies
have not been published.
NEWBORN SCREENING FOLLOW-UP
Workshop discussions regarding patient follow-up were consistent with those of the
Newborn Screening Task Force meeting, which was convened by the American Acad-
emy of Pediatrics in Washington, D.C. in 1999 (1 ); therefore, proposals regarding follow-
up concerns are limited in this report. Newborn screening follow-up includes short- and
long-term components. Short-term follow-up tracks patients from a positive test result
through diagnosis and acknowledgment by a health-care provider of that diagnosis.
Long-term follow-up tracks patients from diagnosis through clinical management and
beyond to ensure that they and their family members receive needed services.
Work Group Proposals
• The same short-term follow-up approach should be followed for MS/MS-
detectable disorders as for conditions in which delayed treatment poses a high
risk of fatal outcomes and for which timely transport of test samples and analysis
are essential (e.g., galactosemia and congenital adrenal hyperplasia). For
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metabolic disorders in which usual feeding practices might result in acute crisis
and risk of death, upon notification of an initial abnormal test result, physicians
should advise parents of what short-term feeding measures to take in advance of
repeat and confirmatory tests so as to avert a potentially lethal crisis (33 ). In the
case of MCAD deficiency, an infant who experiences fasting as the result of loss of
appetite is at risk of hypoglycemic crisis, which is preventable if parents ensure
that children eat regularly (34 ).
• Although reported false-positive rates are low and metabolic disorders are rare,
an increase in the number of diagnosed disorders will require additional follow-up
personnel and definitive diagnostic services. Newborn screening program
personnel will need technical and resource assistance with developing
educational materials and in training staff and health-care providers in follow-up
procedures for MS/MS-detectable conditions.
• To conduct adequate long-term follow-up, programs will need to establish or
improve patient-tracking systems. Ideally, data management for such a system
would include registries to which treatment centers continually provide updated
information, treatment compliance, and outcomes.
DIAGNOSIS AND TREATMENT
MS/MS technology can assist in diagnosing metabolic disorders during the newborn
period that previously were diagnosed only after symptoms developed. Presymptomatic
detection now allows treatment initiation while the infant is healthy and assists in defin-
ing the spectrum of clinical disease related to these disorders. MS/MS technology can be
used advantageously to screen for selected amino acid disorders for which other new-
born screening methods are used. For example, MS/MS can accurately detect elevated
phenylalanine levels in dried blood spots taken from infants as young as age <24 hours.
By using the MS/MS-detected phenylalanine/tyrosine ratios, physicians can diagnose
PKU earlier and rely on an assay with a reduced false-positive rate (6 ).
For policymakers and program managers, the uncertainty of outcomes from early
diagnosis complicates deciding whether to use MS/MS for newborn screening. For
example, presymptomatic MCAD-deficiency detection might lead to decreased morbid-
ity and mortality among infants, whereas evidence regarding outcomes for other fatty
acid oxidation disorders is lacking (35 ). Because data are still limited, additional research
is needed to determine what interventions work for MS/MS-detectable metabolic disor-
ders. Consensus is lacking regarding which disorders should be included in a MS/MS
screening panel and for defining a list of mandated tests in the panel. Additional pilot
testing is required. Another challenge to the definitive diagnosis of metabolic disease is
that persons with one of these disorders might by affected in different degrees of sever-
ity (i.e., clinical heterogeneity) with varying physical and biochemical manifestations.
Opinions differ as to where to draw the line on the diagnosis of infants as affected or not
by a particular disorder. In using MS/MS technology, clinical heterogeneity presents
challenges in setting cutoffs to minimize the frequency of false-positive and to prevent
false-negative results. The full clinical spectrum of metabolic disorders is unknown
because certain MS/MS-detectable disorders are rare and not well-described in the
literature. Further, even for classical cases, different mutations in DNA (deoxyribonucleic
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acid) can exist. Milder variants exist also, and their natural history is unclear. The term
milder variant  is based on the discovery of a mutation that does not correlate with
clinical symptoms and is recognized only when a particular stress is placed on the
affected child. Newborns with mild or late-onset variants of metabolic disorders are
more likely to be missed by MS/MS. Conclusions based on the outcomes of limited num-
bers of reported cases are not valid assessments of variants; therefore, prevalence data
for variant cases will be sparse until statistically significant numbers of test results are
collected and analyzed.
In conjunction with diagnostic questions needing additional research, treatment out-
comes are of concern for policymakers and program managers considering MS/MS for
newborn screening. Again, long-term studies are needed to evaluate whether outcomes
are improved as a result of MS/MS screening and early diagnosis. Clinical treatment and
long-term care services are costly; therefore, treatment expense and funding resources
for support services are of concern.
Work Group Proposals
• To take advantage of MS/MS technology for detecting abnormal metabolite levels
among newborns, many of which are present during the first week of life, rapid
transport of blood-spot specimens to the screening laboratory is required. The
time from birth to diagnosis should be as short as possible, with an ideal time
frame of <5 days.
• Efforts should be made to reduce handling time within hospitals to decrease time
to analysis.
• Optimal specimen transport time from the hospital to the laboratory is <24 hours,
but transport time of <48 hours is critical. Program managers should consider
using courier services and requiring 24-hour delivery of specimens to the
laboratory. To ensure delivery, program managers should have contingency
plans in place.
• A 6-day work schedule for MS/MS laboratories performing newborn screening is
preferable because the first analysis should be performed within a 24-hour
turnaround time, with another <24 hours for retesting and confirmation if test
results indicate abnormal levels.
• For all infants suspected of having a metabolic disorder, confirmatory testing,
using published standard metabolic testing procedures, should be performed
before treatment. Different criteria should be used for diagnostic confirmation
testing, but MS/MS technology can be used also.
• Acylcarnitine analysis performed by an MS/MS laboratory is valid for specimens
from newborns but might not be for specimens from older infants. Duplicating an
analysis by the same or another laboratory adds only limited information, and the
results could be misleading. Laboratory results should be correlated with the
clinical status. If available, a DNA analysis for common mutations in the disorder
would provide further confirmation of the disease.
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• Treatment resources might be inadequate as a result of the rarity of metabolic
diseases among newborns; therefore, ensuring delivery of clinical services can
be a logistical and funding challenge for health-care providers. Access to
treatment services that includes specialized care centers, nutritionists, social
workers, certified genetics counselors, and specially prepared medically required
foods must be ensured before screening is introduced.
• Because of the emotional and financial burden that care, treatment, and
outcomes for newborns with MS/MS-detectable metabolic conditions pose on the
families, clinicians should communicate concerns and treatment options carefully
to parents of possibly affected children (1,15 ).
MS/MS SCREENING EVALUATION
The Newborn Screening Task Force recommends that state and territorial health
agencies
• include evaluation, performance monitoring, and quality assurance activities in
their newborn screening systems;
• conduct oversight of program operations; and
• monitor and evaluate program performance through collection, assembly,
analysis, and reporting of data, including outcome evaluations (1 ).
Specifically, the evaluation of a screening program involves examining the clinical
validity (i.e., sensitivity and specificity, positive or negative predictive values), clinical
utility (i.e., improvement in health or development outcomes with early treatment), and
cost-effectiveness of the screening protocol for each disorder (36 ). Pilot demonstration
programs in states could provide information regarding certain variables if they had
adequate resources to acquire and report technical and clinical results (15 ). Determina-
tion of false-positives, specificity, and positive predictive value is straightforward and can
be calculated using a data system that tracks infants from initial test results through
diagnosis. Remaining variables require development of more sophisticated and collabo-
rative data collection systems, particularly for evaluating the clinical utility of screening,
which for any given disorder, depends on the demonstration that early treatment
improves long-term outcomes.
Work Group Proposals
• Long-term storage of leftover specimens is a critical consideration for newborn
screening programs. Leftover specimen storage and use should be guided by
policies and procedures that include protection against their inappropriate use
(1 ). Retention of blood-spot specimens could be pivotal in determining false-
negative rates (1 ). False-negatives can be confirmed only by identification of an
affected patient clinically or through autopsy findings, and comparing those
findings with results obtained by retesting the original blood spot and using
storage-control specimens. Correct storage of specimens is required for this
process (15 ).
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• A key challenge to using MS/MS for expanded newborn screening is the lack of
published scientific data regarding MS/MS-detectable disorders among
newborns. Specifically, data are needed regarding the results of diagnosis and
treatment to justify the expanded screening. Expert opinion regarding the
justification for performing expanded screening varies substantially (1 ). A list of
the disorders detectable by MS/MS are provided in this report (Table 1). Expert
reviewers have concluded that MCAD, one of the disorders that requires MS/MS
screening, meets almost all of the criteria to justify newborn screening, and these
reviewers recommend collecting additional data through pilot MS/MS screening
programs (35,37,38 ). MS/MS also offers certain advantages over traditional
methods for detection of PKU and other amino acid disorders (25,28 ).
• Although certain newborn screening programs are expanding without scientific
support, program managers should incorporate epidemiologic research methods
into implementation efforts so that evaluation results can be used by others facing
this challenge.
• To assess the utility of expanded MS/MS screening, national data regarding
screening performance and outcomes should be collected. No mechanism
beyond the National Newborn Screening and Genetics Resource Center’s report
is in place for collection of these data. Federal agencies could support the design
and implementation of projects targeted for gathering data and retrospectively
analyzing the experience of expanded newborn screening programs, but such
projects first require development of uniform data reporting protocols. In
particular, such projects would require agreement regarding consistent case
definitions, including normalization of cutoffs.
• Routine data collection by a single state program is unlikely to be sufficient to
evaluate the long-term outcomes of screening for these conditions. Constructing
prospective cohorts of patients with rare disorders, although expensive, is one
way to address issues of the true incidence and prognosis of these disorders.
Prospective cohorts have been constructed for other diseases, notably childhood
cancers and hemophilia. Another relevant model for expanded screening
research is the multicenter registry of cystic fibrosis patients coordinated and
supported by the Cystic Fibrosis Foundation. A federally funded multicenter study
could track newborns with positive test results and actively pursue other clinically
detected cases. This study would require a substantial long-term funding
commitment and would require the expertise and cooperation of epidemiologists
and health services researchers in multiple federal agencies.
• Collection of economic data regarding costs and cost savings is essential for
analyzing the cost-effectiveness of screening. Collecting economic data requires
improved coding techniques for inborn errors of metabolism so that use of health-
care services is consistently recorded. Consistent recording would allow financial
data collection to justify continuation of programs or third-party–payer
reimbursement.
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• An epidemiologic perspective should bring additional benefits (e.g., definitions of
minimal essential data and improved data coding). Other strategies besides
prospective cohort methods are possible. For example, data from medical
examiners in different states has led to the realization that some sudden and
unexplained childhood deaths can be attributed to specific inborn errors of
metabolism with a higher frequency than previously recognized.
• Public health officials and newborn screening program managers evaluate
screening systems differently than parents of affected children, primary-care
providers, and the public do. Public health officials and program managers focus
on positive and negative predictive values and clinical utility. In contrast, the
public and physicians without substantial experience with these disorders lack
understanding regarding screening and might have unrealistic expectations for
treatment outcomes. Both parents and health professionals need to be educated
regarding limitations and availability of expanded newborn screening (1,15 ).
CONCLUSION
The goals of the 2000 workshop were to provide guidance for newborn screening
program managers and policymakers who are using or planning to use MS/MS technol-
ogy; workshop goals did not include recommending screening for specific MS/MS-
detectable disorders. Interest in using MS/MS technology for newborn screening for
an expanded range of inheritable metabolic disorders is increasing throughout the United
States. A limited number of public health screening laboratories have introduced MS/MS
with minimal difficulty. Others have started MS/MS testing with a limited understanding
of MS/MS applications and detectable disorders; those programs have found installation
and use of MS/MS instrumentation to be a substantial undertaking. In certain cases,
overall system concerns have not received adequate consideration (1 ). The American
College of Medical Genetics and the American Society of Human Genetics state
that “. . . MS/MS can provide substantial benefit to patients and their families, if thought-
fully integrated into newborn screening programs” (15 ). However, the need to monitor
MS/MS screening programs on a collaborative basis, with periodic reappraisal of goals
and achievements, is now recognized, and different groups are beginning to work
together to better assess concerns, solutions, and outcomes of MS/MS testing.
The overall consensus of the workshop participants is that the public should receive
accurate information regarding expanded and comprehensive newborn screening and
the evolving knowledge regarding its strengths and weaknesses. State programs that
are ensuring universal opportunity, quality control, tracking, and follow-up should con-
tinue without interruption. Additional disorders other than metabolic disorders detected
by MS/MS are included in comprehensive screening (e.g., congenital adrenal hyperpla-
sia, cystic fibrosis, sickle cell disease, and biotinidase deficiency). Expansion of screening
should include the more common disorders that are available in certain programs (1 ).
Work Group Proposals
As a result of information shared at the 2000 workshop and efforts of the work group,
the following overall proposals are offered:
State and territorial health agencies should
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• consider using MS/MS and other expanded newborn screening technologies and
actively participate in future workshops because these agencies are the direct
sources of funding and regulations for prevention efforts. As research and
reported data grow regarding MS/MS for newborn screening, public health
agencies will want to access this technology either directly or through regional
agreements. Staying current with technological developments will be critical for
policymakers and program managers.
• anticipate difficulties in implementing MS/MS testing because the technology
requires new, expanded, and expensive resources. Those resources include
— investments in equipment;
— expanded information technology support for interpretation, reporting,
tracking, and outcome evaluation;
— staff training in clinical and laboratory aspects of detectable disorders;
— access to reference laboratories for confirmation of diagnosis; and
— assurance of access to adequately skilled clinicians for treatment and
counseling.
• involve health-care practitioners, laboratory directors, birthing hospitals, parents,
lay advocacy groups, and third-party payers in a collaborative effort to plan and
define the state and territorial programs and obtain the legal authority and
funding necessary for implementation.
• consider contracting with other state laboratories, private laboratories, or
academic medical centers for laboratory services that are too expensive for local
program resources. Alternatively, information could be provided to health-care
practitioners, hospitals, and parents explaining the options for supplemental
testing services, and state/territorial program staff could facilitate access to these
services. States that contract for laboratory or other services should retain the
functions of quality assurance and monitoring (e.g., speed and accuracy of testing
and reporting, tracking, and ensuring quality clinical follow-up).
Federal health agencies should
• provide leadership and support to assist states and territories in implementing
MS/MS technology. An effective model for federal involvement in newborn
screening is the assistance that was provided to states and territories when
implementing sickle cell disease testing. A 1986 National Institutes of Health
consensus development conference (39 ) recommended sickle cell disease
screening for newborns. Congress then appropriated $8 million for the Special
Projects of Regional and National Significance program administered by HRSA.
Using that funding, HRSA awarded grants to enhance the screening
infrastructure. States then reviewed the scientific information, appropriated
funding, and added sickle cell disease to their newborn screening programs. CDC,
in cooperation with HRSA, developed a quality-assurance program and funded
studies for effectiveness evaluation of sickle cell screening methods and
programs.
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• support a national MS/MS screening work group with three subcommittees,
— a laboratory methods group to address standards, quality assurance, and
methodologic improvements;
— a clinical group to define the detectable disorders, available interventions, and
requirements for metabolic diagnosis and management; and
— an epidemiologic group to design and implement an evaluation effort that
would include collecting data regarding effectiveness of different screening
policies, disorder prevalence and trends, long-term outcomes, and cost-
effectiveness and cost-benefit.
Representatives from the American Academy of Pediatrics, American College of
Medical Genetics, American Public Health Association, Association of Public Health
Laboratories, Association of State and Territorial Health Officers, National New-
born Screening and Genetics Resource Center, CDC, and HRSA should
actively participate in workshop, work group, and subcommittee activities.
• sponsor long-term epidemiologic studies of MS/MS screening to document the
natural history of metabolic diseases, establish data collection protocols, and
evaluate MS/MS technology’s impact.
• provide resources to support state and local staff training in MS/MS analytic
techniques and efforts to provide analytical standards and proficiency testing.
• provide fiscal and technical support for long-term follow-up, large-scale data
sharing, or development of laboratory quality-assurance programs to prevent
MS/MS applications of mixed quality and effectiveness resulting from
independent and isolated actions.
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Appendix
Synopses of Selected Papers
Presented at the Tandem Mass Spectrometry
for Metabolic Disease Screening
Among Newborns Workshop, San Antonio, Texas, June 2000
Scientists from all operating tandem mass spectrometry (MS/MS) newborn screen-
ing laboratories and programs in the United States — public health, academic, and
private — and two international experts (Rodney J. Pollitt, Ph.D., United Kingdom and
Bridget Wilcken, M.B., Ch.B., Australia) were invited as discussants for the workshop held
in June 2000. The discussant group included the pioneers of MS/MS applications in
newborn screening, Charles R. Roe, M.D.; Donald H. Chace, Ph.D.; David S. Millington,
Ph.D.; and Edwin W. Naylor, Ph.D., as well as scientists from the two companies that
manufacture MS/MS equipment used for newborn screening. The workshop was a joint
effort that involved cooperation among public health agencies, academic institutions,
and the private sector with shared interest in enhancing the use and quality of MS/MS
technology. Approximately 50 observers from newborn screening programs in the United
States with future expectations for using MS/MS also attended the workshop.
Each invited discussant was asked to provide a 1-page summary relating their expe-
riences with MS/MS for any of the applicable parameters (e.g., setting-up and operating
MS/MS, selection of cutoffs, associated follow-up of infants with identified disorders,
medical confirmation of disorders, and treatment of disorders). Summaries were sub-
mitted of presentations given at the plenary session and breakout group meetings. In-
vited discussants were also asked to provide a list of what they believed were the 5–10
most important questions, in a priority order, regarding the application and needs for MS/
MS in screening, confirmation, quality assurance, follow-up, and treatment of metabolic
disorders among newborns. These presentations, summaries, and lists of questions were
used to guide breakout groups in their deliberations and discussions for the development
of work group proposals for MS/MS in newborn screening. Selected synopses of
summary papers that represent the context of the workshop are presented here.
SELECTED PRESENTATIONS REGARDING LABORATORY PRACTICE
Testing Newborn Specimens by Tandem Mass Spectrometry: The First 16 Months’
Experience in the New England Program — Thomas H. Zytkovicz, Ph.D.; Donna
Johnson; Denise Rojas, M.P.H.; Eileen Fitzgerald; New England Newborn Screening
Program, Jamaica Plain, Massachusetts
On February 1, 1999, the New England Newborn Screening Program began using
tandem mass spectrometry (MS/MS) to test newborns for 23 disorders, including 9 amino
acid disorders, 7 organic aciduria disorders, and 7 fatty acid oxidation disorders. How-
ever, before using MS/MS, we validated the experimental method.* MS/MS instrument
*Source: Rashed MS, Bucknall MP, Little D, et al. Screening blood spots for inborn errors of
metabolism by electrospray tandem mass spectrometry with a microplate batch process
and a computer algorithm for automated flagging of abnormal profiles. Clin Chem
1997;43:1129–41.
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bias was determined by comparing test results with preexisting analytical methods (e.g.,
high-pressure liquid chromatography and bacterial inhibition assay). Blood controls were
prepared by fortifying samples with amino acids and acylcarnitines and sending these
samples to other laboratories for MS/MS analysis of the markers. These interlaboratory
results were used to compare our laboratory’s performance with that of established
laboratories. Approximately 170,400 newborns were tested for phenylketonuria, maple
syrup urine disease, and homocystinuria. MS/MS identified six infants with phenylketo-
nuria, nine with hyperphenylalaninemia, one with maple syrup urine disease, and three
infants with homocystinuria/hypermethionemia. Approximately 100,000 newborns were
tested for 20 other disorders. MS/MS tentatively identified seven infants with medium-
chain acyl-CoA dehydrogenase; four with short-chain acyl-CoA dehydrogenase; two
with phenolic acid; and one each with methylcrotonyl-CoA carboxylase; carnitine
palmitoyl transferase, type II; and very-long–chain acyl-CoA dehydrogenase. The major-
ity of these infants are undergoing DNA (deoxyribonucleic acid), urine, or in vitro testing
to confirm MS/MS diagnoses.
Comprehensive, High-Quality Analytical Approach to Newborn Screening Using
Tandem Mass Spectrometry — Donald H. Chace, Ph.D.; Neo Gen Screening, Inc.,
Bridgeville, Pennsylvania
Because MS/MS technology can be used for screening multiple disorders in a single
analysis, low-prevalence disorders can be included with higher prevalence analytes
without a substantial additional cost. However, MS/MS screening results require inter-
pretation by experienced metabolic specialists and confirmation by other analytical or
diagnostic techniques. MS/MS uses stable isotope internal standards as an essential
component of the method, and therefore, it is precise and accurate in controlled tests.
Nevertheless, blood volume from filter paper blood-spot specimens can be inaccurate
and reduce the reproducibility of MS/MS that is observed in analyses of liquid specimens
(e.g., serum or plasma). Ratios of >2 components improve diagnostic accuracy and
reproducibility that otherwise would be lost by using filter paper blood-spot specimens.
As this emerging technology develops, sample preparation, analyses, data processing,
and interpretations will be modified. New assays will expand the current panel of MS/
MS-detectable disorders or provide a source for confirmation. Further, as genetic testing
expands to include additional molecular approaches, complementation of these meth-
ods will provide comprehensive analyses that will better serve public health needs.
Introduction of Tandem Mass Spectrometry Into the Newborn Screening
Environment — Michael R. Morris, Ph.D.; Micromass United Kingdom Ltd.,
Manchester, United Kingdom
Personnel training and laboratory support can resolve certain problems related to
introducing tandem mass spectrometry for newborn screening, but program managers
must develop their own experiences before determining that MS/MS is a stable tool to be
used in routine newborn screening. Although a detailed knowledge of physics and instru-
ment operation is unnecessary, program managers and laboratorians should under-
stand basic operational details. High-throughput screening of extracted blood samples is
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an exacting test, and certain critical factors must be considered to maintain optimum
instrument performance, including the following:
• Sample preparation. If samples are prepared in a substandard manner, the
validity of the assay becomes questionable. Addition of internal standard
materials at the beginning of the extraction procedure allows monitoring of the
extraction and derivatization as well as instrument performance. Quality of
solvents, standards, and other materials used in sample preparation procedures
must be assessed for suitability.
• Instrument sensitivity. Using a benchmark solution to visually check instrument
performance at the start of a day’s work can identify problems in a timely manner.
Injection of a standard sample that can be monitored in real time can give the
experienced user information regarding the status of the flow path and injection
system, the cleanliness of the ion source, and the status of the mass calibration.
Users become adept at rapidly drawing conclusions on the basis of the arrival
time of the sample after injection, the location of the individual peaks on the mass
scale, the instrument resolution, and the absolute and relative intensities of the
peaks.
• Sample inlet system blockages. Investigative samples contain a substantial
number of organic-soluble compounds and have the potential to introduce
particulate matter. A logical assessment of the liquid-flow path and regular
monitoring of the back-pressure of the liquid chromatography pump will increase
efficiency.
• Use of operational qualification and quality-control samples. Ideally, quality-
control samples should be used to monitor the performance of the assay for all
compounds of interest. Practically, monitoring an individual compound from each
class of analytes being measured might be sufficient to prove analytical
effectiveness. Also, tests should be run to ensure that particular internal
standards are present at the correct concentration.
Laboratories that have played key roles in introducing MS/MS into newborn screen-
ing have developed cross-checks to monitor assay performance and provide analytical
safeguards. In addition, interlaboratory communication that focuses on emerging prob-
lems and possible solutions is strongly recommended.
Selection of Reporting Cutoffs in Newborn Screening: Patient-to-Normal Ratio —
Joerg N. Pirl, Ph.D.; Rong Shao, M.D.; Michael Petros, M.S., M.P.H.; Illinois Department
of Public Health, Chicago, Illinois
The selection process for reporting cutoffs is based on statistical evaluations of his-
torical patient data, which might change as methods and procedures are updated, thus
producing a substantial number of false-positive results. Because test results are method-
dependent, reference ranges or normal values are needed for interpretation. If the
patient results are expressed relative to that normal value, the resulting patient-to-
normal ratio (PNR) is a unitless number that is a measure of the deviation of the patient
result from that of the normal population. When normal values are calculated from
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within-run data, uniform variations associated with matrix, calibration, recovery,
accuracy, and instrument will cancel. In a newborn screening laboratory, approximately
95% of samples received are from patients with normal levels, and PNRs derived from
patients analyzed under approximately identical circumstances are method-
independent and, thus, interlaboratory comparable.*
We compared rapid-flow analysis (RFA) and MS/MS phenylalanine (phe) results from
approximately 14,000 neonatal dried blood spots. Included were 267 patients with levels
above our RFA cutoff of 4.0 mg/dL and 45 patients with confirmed phenylketonuria or
hyperphenylalaninemia. For newborns with normal levels, concentrations of phe were
usually distributed around the mean. When the results were arranged in ascending
order, the result of the median patient agreed closely with the mean of the median 68%
(mean ± 1 standard deviation [SD]) and 95% (mean ± 2 SD) of the population. This
agreement was true also for ratios of phe to selected other amino acids. The median
deviated by <1% from the 68% and 95% population mean, and the concentration of phe
as well as the ratio of phe to the other amino acids was linearly related to the median
60% of the normal patients with a slope near zero; for phe, the slope was 0.00087
mg/dL/patient. That is, when results were sorted numerically, this group of patients had
the same or nearly the same results. For any given routine run (i.e., MS/MS or RFA, with
a minimum of one 96-well microplate) the result of the median patient (patients arranged
in ascending order) differed <3% from the mean of the central 68% and <5% from the
central 95% mean. MS/MS, in light of its high analyte specificity, produced a lower phe
concentration than RFA but did not substantially improve the predictability for disease-
correlation coefficient, MS/MS versus RFA >0.9. RFA positive predictive value was 18.2%.
To examine internal metabolite ratios and to minimize effects from specimen quality or
feeding, in addition to phe, we also analyzed these patients by MS/MS for leucine (leu),
methionine (met), tyrosine (tyr), alanine (ala), valine (val), and serine (ser).
PNR was calculated for phe, phe/leu, phe/met, phe/tyr, phe/ala, phe/val, and phe/ser
by dividing the results of the patients by the median result for that parameter, with results
sorted numerically. The final output presented the PNR values for phe and those of the
internal metabolic ratios in tabular form. PNR-phe/tyr of <2.0 was associated with nor-
malcy. The lowest PNR-phe/tyr in hyperphenylalaninemia patients was 2.36 and 4.62 in
cases of classic phenylketonuria. The positive predictive value was 83.8% if PNR for all
internal ratios was considered and 38.4% on the basis of PNR for phe/tyr only. The
negative predictive value was 100% in all cases.
Implementation of Tandem Mass Spectrometry in Wisconsin’s Newborn Screening
Program — Gary L. Hoffman; Thomas Litsheim; Ronald H. Laessig, Ph.D.; Wisconsin
State Laboratory of Hygiene, Madison, Wisconsin
After we acquired a tandem mass spectrometry (MS/MS) instrument to measure
acylcarnitines in dried blood specimens, we devoted approximately 1 month to learning
its operation. This learning period consisted of a) one, 2-day session with the service
engineer during the setup reviewing instrument calibration and routine maintenance
requirements; b) two, 3-day sessions with instrument manufacturer’s application
specialists to establish sample preparation, method calibration, and data reduction;
c) 1 week independently developing a comfort level with instrument operation; and
*Source: Hubbard AR, Margetts SML, Barrowcliffe TW. International normalized ratio
determination using calibrated reference plasmas. Br J Haematol 1997;98:74–8.
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d) 1 week at a training course at the manufacturer’s facility. This training enabled us to
begin pilot testing.
One of the goals of the pilot testing phase was to collect acylcarnitine data to establish
reporting profiles for fatty acid oxidation and organic aciduria disorders. The first step
was a literature review of the acylcarnitines associated with each of the 14 fatty acid
oxidation and organic aciduria disorders mandated by the Wisconsin Department of
Health’s Newborn Screening Advisory Committee. Although published literature does
not agree on the acylcarnitine profile for each disorder, we established a composite
profile for each one. After collecting 5,000 random observations for each acylcarnitine,
we established an abnormal reporting level at the mean concentrations plus four stan-
dard deviations. We further adjusted these abnormal reporting levels as follows:
a) comparing them against those already published by other laboratories using MS/MS
to identify newborns with these 14 metabolic disorders, and b) consulting with an expe-
rienced metabolic expert in the clinical diagnosis of these disorders. For the majority of
acylcarnitines, the four standard deviation level was maintained, although certain ad-
justments were made that increased the cutoff of some acylcarnitines to >5 standard
deviations from the mean. In addition to acylcarnitine levels, we added multiple concen-
tration ratio-based criteria to the abnormal profiles for certain disorders. Using this pre-
liminary criteria, we referred 13 babies for confirmatory testing from the approximately
50,000 specimens screened during the pilot study. Five (i.e., four medium-chain acyl-CoA
dehydrogenase and one short-chain acyl-CoA dehydrogenase disorders) were confirmed.
A secondary goal of the pilot study was to determine how the MS/MS technology
could be incorporated into the routine newborn screening operation. A primary focus
was on the ability of the MS/MS instrumentation to process the specimens in a timely
manner (i.e., <24 hours after receipt) so delay in reporting all results would be minimal.
With modifications, we reduced sample preparation time to <10 minutes after punching*
the sample from the blood-spot specimen. Because the instruments’ throughput is
1 sample/1.5 minutes and it can operate overnight unattended, the system could handle
500 samples/day. On the basis of the success of the pilot testing phase, which established
abnormal reporting levels and instrument reliability, we began routine testing for 14
metabolic disorders by MS/MS in April 2000.
*Punching  is a procedure that takes an aliquot portion (e.g., 1/8 inch) from the dried blood
spot contained on the filter paper.
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SELECTED PRESENTATIONS REGARDING
NEWBORN SCREENING FOLLOW-UP
Incidence and Follow-Up Evaluation of Metabolic Disorders Detected by Newborn
Screening in North Carolina Using Tandem Mass Spectrometry — Joseph Muenzer,
M.D.; Dianne M. Frazier, Ph.D.; Shawn E. McCandless, M.D.; University of North
Carolina, Chapel Hill, North Carolina; Elizabeth G. Moore, M.S.W.; Susan D. Weavil;
Shu H. Chaing, Ph.D.; Department of Health and Human Services, Raleigh, North
Carolina; David S. Millington, Ph.D.; Duke University Medical Center, Research
Triangle Park, North Carolina
Since August 1997, the North Carolina Newborn Screening Program has been screen-
ing all newborn infants by using tandem mass spectrometry (MS/MS) for selected amino
acid, organic acid, and fatty acid oxidation disorders. Initially, a statewide pilot study
lasting 20 months was conducted, and on the basis of that pilot study, the North Carolina
Newborn Screening Program incorporated MS/MS screening into the state newborn
screening panel. During the pilot study, Neo Gen Screening, Inc., (Bridgeville, Pennsylva-
nia) screened 194,384 newborns (214,634 specimens) and identified 259 (0.13%) samples
as abnormal. Metabolic disorders were confirmed for 31 infants; results indicated that
14 children had medium-chain acyl-CoA dehydrogenase deficiency; 1, long-chain fatty
acid oxidation disorder; 6, hyperphenylalaninemia; 1, hypermethionemia; 3, citrullinemia;
1, argininosuccinic aciduria; and 5, organic aciduria disorders.
During a subsequent phase of implementation (April 1999–June 2000), the North
Carolina Newborn Screening Laboratory screened 131,776 newborns (147,286 speci-
mens). Initial cutoffs resulted in false-positive detection rates of >1.9%, but revised cut-
offs resulted in a <0.85% false-positive rate. Metabolic disorders were confirmed for
27 infants; results indicated that 10 children had medium-chain acyl-CoA dehydrogenase
deficiency; 1, short-chain acyl-CoA dehydrogenase deficiency; 9, hyper-
phenylalaninemia; and 7, organic aciduria disorders. Since MS/MS screening began in
North Carolina, disorders among three infants (one with late-onset methylmalonic aci-
demia and two with glutaric acidemia, type I) were missed by MS/MS screening, but the
disorders were diagnosed clinically before age 1 year for all three infants.
Patient follow-up in North Carolina is coordinated by the Division of Genetics and
Metabolism, Department of Pediatrics, University of North Carolina at Chapel Hill (UNC).
A two-tier follow-up approach has been used with abnormal MS/MS screening results.
When the MS/MS results indicate an inborn error of metabolism, the screening labora-
tory notifies UNC by telephone and facsimile. UNC staff then contact the local health-care
provider by using information provided on the newborn screening card. Follow-up evalu-
ation and recommendations for additional testing, on the basis of the MS/MS laboratory
findings, are made by UNC personnel so the suspected diagnosis can be confirmed, the
family counseled, and treatment initiated. Initial MS/MS screening results that are bor-
derline (i.e., a possible inborn error of metabolism) require repeat testing. If a second
specimen indicates abnormal levels, UNC staff coordinate additional testing (i.e., for
abnormal amino acids, a plasma amino acid analysis is run; for an abnormal acylcarnitine
profile, plasma acylcarnitine profile and urinary organic acid analyses are run).
All infants in North Carolina with medium-chain acyl-CoA dehydrogenase deficiency
detected by newborn screening are treated with carnitine and are maintained on breast
milk or infant formula with no fat restriction to age 1 year. Parents are instructed to avoid
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prolonged fasting and to use a glucometer to monitor blood glucose levels when they are
concerned regarding the child’s oral intake or clinical status. No deaths, significant
hypoglycemic events, or seizures have occurred among the infants with medium-chain
acyl-CoA dehydrogenase deficiency identified by newborn screening. Screening by MS/
MS, with careful follow-up, can prevent the majority of deaths and serious sequelae of
medium-chain acyl-CoA dehydrogenase deficiency during the first years of life. How-
ever, MS/MS is not entirely specific for this error of metabolism and detection of abnor-
mal but nondiagnostic metabolites can occur. Since MS/MS analysis began in the North
Carolina Newborn Screening Laboratory, borderline results have been common with
propionyl-acylcarnitine, 3-hydroxy-isovalerylcarnitine (C5-OH), and tyrosine. Adjustment
of cutoff levels has reduced the false-positive rate, but additional adjustment might be
needed on the basis of follow-up evaluation of the borderline results. Close coordination
between the MS/MS screening laboratory and the metabolic clinic/biochemical geneti-
cists is needed to determine screening parameters, adjust the cutoff levels to reduce
false-positive and false-negative results, and facilitate clinical follow-up.
Notification Experience with Newborn Disorders Detected by Tandem Mass
Spectrometry in the Early Experience of the New England Program — George F.
Grady, M.D.; Thomas H. Zytkovicz, Ph.D.; Deborah Marsden, M.D.; Cecilia Larson,
M.D.; Vivian Shih, M.D.; New England Newborn Screening Program, Jamaica Plain,
Massachusetts
A series of protocols has emerged for notifying pediatricians when a newborn under
their care is identified by tandem mass spectrometry (MS/MS) screening as having an
out-of-range amino acid or acylcarnitine value. For the amino acids, phenylalanine (for
phenylketonuria [PKU] or hyperphenylalaninemia [HPA]), leucine plus isoleucine (for
maple syrup urine disease [MSUD]), and methionine (for homocystinuria [HCU]), the
MS/MS analysis was performed for approximately 171,500 newborns. The net yield of
confirmed (repeatedly positive) cases was similar to that during the prior era of bacterial
inhibition assay (i.e., six PKU plus nine HPA, one MSUD, and one HCU plus two
hypermethionemia). Persistence of biological confounders affected clinical interpreta-
tion of the phenylalanine, leucine, or methionine for 102 newborns, who required repeat
specimens because of immaturity or systemic illness.
For approximately 109,400 newborns, the screening profile by MS/MS included sepa-
rate recordings of tyrosine and the basic amino acids, ornithine, citrulline, and arginine.
Testing repeat specimens from 24 infants with an initial elevation of tyrosine, and from
24 infants who had initial elevations of ornithine, citrulline, or arginine, yielded no con-
firmed cases of specific disorders that would have explained the elevations. Neverthe-
less, when physicians associated with our screening program staff contacted the infants’
physicians regarding the elevation, our staff provided information regarding potential
signs and symptoms and possible future interventions.
The 109,400 newborns were also screened by MS/MS for certain acylcarnitines that
had side chains containing <18 carbons (e.g., C18), to detect fatty acid oxidation and
organic aciduria disorders. For an additional 10,000 infants, only the medium-chain
acylcarnitines were measured. Among those infants whose test results indicated fatty
acid oxidation disorders, the medium-chain candidate group included 36 infants of whom
a) two had an initial C8 of 9–10  µM (the parents were referred immediately to metabolic
clinics); b) five had an initial C8 of 1.8–3.2  µM (parents were given the option of direct
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referral or awaiting results of C8 on a second specimen before deoxyribonucleic acid or
urinary acylglycine analysis); and c) 29 had an initial C8 elevation of 0.5–0.8  µM. The
cases in group a were homozygous for the A985G marker; group b was incompletely
analyzed but includes ones with positive urinary samples or a single copy of A985G; and
group c revealed no elevated C8 on repeat testing and the deoxyribonucleic acid assay
was left to personal choice. Upon initial notification, all pediatricians were asked to verify
feeding status of the infant and to advise parents to avoid gaps in feeding.
Fatty acid oxidation disorder detections also included four presumptive cases of short-
chain acyl-CoA dehydrogenase deficiency that had initially elevated butyrylcarnitine, C4
(range: 2.6–3.7 µM), persisting on a repeat specimen or accompanied by the respective
urine acylglycine, deoxyribonucleic acid, or in vitro markers. In 19 other newborns, initial
elevations of C4 (>1.9  µM) did not persist (the notification protocol was analogous to the
medium-chain protocol). The remaining four notifications included two with an initial
elevation of C16, one of which was a fatal case of carnitine palmitoyl transferase, type 2;
and two with elevated C14:1, one of which was confirmed as very long-chain acyl-CoA
dehydrogenase deficiency.
Organic aciduria disorder detections included two propionic acidemias (among
23 notifications when propionylcarnitine, C3, was >8  µM) and one beta-methylcrotonyl
CoA carboxylase deficiency (among 12 notifications of C5 OH >0.8  µM). Because early
onset central nervous system problems were a greater concern for this disorder than for
fatty acid oxidation disorder, notification protocols were more aggressive in spite of
lower specificity of the initial elevated marker.
Newborn Screening for Medium-Chain Acyl-CoA Dehydrogenase Deficiency —
Sophia S. Wang, Ph.D.; National Center for Environmental Health, CDC, Atlanta,
Georgia
Increasingly, programs are screening for medium-chain acyl-CoA dehydrogenase
(MCAD) deficiency among newborns, which has prompted implementation of tandem
mass spectrometry (MS/MS) technology for such testing. If newborn screening pro-
grams conduct systematic follow-up and collect data beyond diagnosis, they can serve
as models to be used in evaluating programs, determining clinical validity and utility, and
providing necessary population-based data. To ensure and evaluate current programs,
the Institute of Medicine’s core functions of public health (i.e., assessment, policy devel-
opment, and assurance and evaluation) should serve as the evaluation framework.*
Program assurance and evaluation requires the collection of key follow-up data beyond
the newborn period to track receipt of services and prevention of adverse outcomes.
Essential data include short- and long-term process and outcome measures.† Key short-
term measures include the percentage of live-born infants adequately screened and the
timeliness of diagnoses and treatment; essential long-term measures include assess-
ment of adverse health outcomes beyond the newborn period. These data are also
essential for developing future programs. Collection of follow-up data also facilitates
*Source: Institute of Medicine. Future of public health. Washington, DC: National Academy
Press, 1988.
†Source: Gordis L. Using epidemiology to evaluate health services. In: Gordis L. Epidemiology.
2nd ed. Philadelphia: WB Saunders Co., 1996:217–28.
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assessment of key test parameters (i.e., clinical validity and utility),* which provide infor-
mation regarding testing accuracy and utility. Clinical validity is defined as how well the
test predicts the phenotype; clinical utility measures the benefits and risks of early detec-
tion for those persons among whom disease is detected. Lastly, systematic collection of
key follow-up parameters can provide needed population-based data regarding these
rare disorders. Data regarding incidence, prevalence, and clinical outcomes can be
determined for the populations being tested and contribute to the elucidation of the
natural history of MCAD deficiency. Furthermore, the penetrance of the mutations asso-
ciated with MCAD deficiency can be investigated. On the basis of rates of heterozygosity
and under Hardy-Weinberg conditions, more MCAD deficiency cases are expected than
are currently observed, leading to a substantial number of infants with asymptomatic
MCAD deficiency and uncertainty as to who will manifest symptoms and who will remain
asymptomatic.† Although diagnosing MCAD deficiency among children is the primary
goal of current newborn screening programs, including systematic collection of key
follow-up data is vital to ensuring optimal functioning and utility of programs.
Grouping Metabolic Disorders Detected by Tandem Mass Spectrometry to Maximize
Political Impact on Legislators and Policymakers — William J. Rhead, M.D., Ph.D.;
Medical College of Wisconsin, Elm Grove, Wisconsin
Effectively presenting tandem mass spectrometry (MS/MS) and universal newborn
screening to legislators and policymakers is an essential preliminary step that differs
from actually implementing expanded programs. When seeking legislative or adminis-
trative approval at the state or territorial level, presenting the screened disorders to
maximize their comprehensibility for persons without scientific or medical backgrounds
is useful. Thus, medium-chain acyl-CoA dehydrogenase disorder, long-chain hydroxy
acyl-CoA dehydrogenase deficiency, and related hypoglycemic disorders could be
grouped and presented under a “low blood sugar” or “sudden infant death syndrome-
like” category. Disorders producing encephalopathy (e.g., hyperammonemias and maple
syrup urine disease) could be grouped together in a “coma” category; and
3-methylcrotonyl carboxylase deficiency and propionic, methylmalonic, and isovaleric
acidemias could be grouped under a “ketoacidotic/acidemic/acid blood” category. These
categories are examples and alternative assemblages or designations can be created to
maximize their political impact. Grouping rare disorders with unpronounceable names
into categories with comprehensible names can accelerate policymakers’ understand-
ing and implementation of MS/MS technology for newborn screening programs.
*Source: Institute of Medicine/Committee for the Study of the Future of Public Health.
Promoting safe and effective genetic testing in the United States: final report of the Task
Force on Genetic Testing. Holtzman NA, Watson MS, eds. Washington, DC: National Academy
Press, 1998:1–180.
†Source: Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl Co-A
dehydrogenase deficiency human genome epidemiology review. Genetics in Medicine
1999;1:332–9.
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SELECTED PRESENTATIONS REGARDING DIAGNOSIS AND TREATMENT
Supplemental Neonatal Screening from Acylcarnitine Analysis Using Tandem Mass
Spectrometry: Reliability and Specificity — Charles R. Roe, M.D.; Baylor University
Medical Center, Dallas, Texas
The majority of the disorders detectable by tandem mass spectrometry (MS/MS) are
characterized by multiple clinical phenotypes.* This phenotypic complexity is com-
pounded by acylcarnitine profiles, which are not always specific for a single disease.
Diseases that are associated with identical or overlapping acylcarnitine profiles include
the following examples:
• Long-chain hydroxy acylcarnitine deficiency is indistinguishable from trifunctional
protein deficiency.
• Carnitine palmitoyltransferase II is indistinguishable from carnitine acylcarnitine
translocase deficiencies.
• The observation of an increase in 3-hydroxy-isovaleryl-carnitine raises the
possibilities of 3-methylcrotonyl-CoA carboxylase, 3-methylglutaconic, hydro-
xymethylglutaryl-CoA lyase, and multiple carboxylase deficiencies.
• An increase in an acylcarnitine containing five carbons can indicate either
isovaleric acidemia or the recently identified S-2-methylbutyryl-CoA dehydroge-
nase deficiency.
Only three disorders exist for which the acylcarnitine profile is completely disease-
specific: medium-chain acyl-CoA dehydrogenase deficiency, glutaric aciduria type I, and
malonic aciduria. Distinctions among diseases that have similar acylcarnitine profiles
can be aided by knowledge of the patient’s clinical course, but that information might not
be available for interpreting abnormal test results before symptom onset. Recent
descriptions of inherited disorders that have the same blood-spot acylcarnitine profile†
emphasize the need for additional documentation to accurately diagnose the specific
disorder and subsequently manage treatment appropriately. Similarly, in vitro demon-
strations have been reported of distinct acylcarnitine profiles for different clinical pheno-
types of the same disease, even with the same mutation.§ Acylcarnitine profiles from
newborn blood spots do not correlate with these clinical phenotypes. Finally, not all
diseases that are potentially detectable by MS/MS acylcarnitine analysis have been
observed among newborns.
*Source: Roe CR, Ding JH. Disorders of mitochondrial function. In: Scriver CR, Beaudet AL, Sly
WS, eds. Metabolic and molecular bases of inherited diseases. New York: McGraw-Hill. 2001.
†Sources: Roe CR, Cederbaum SD, Roe DS, Mardach R, Galindo A, Sweetman L. Isolated
isobutyryl-CoA dehydrogenase deficiency: an unrecognized defect in human valine
metabolism. Mol Genet Metab 1998;65:264–71; and Gibson KM, Burlingame TG, Hogema B,
et al. 2-methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of
L-isoleucine metabolism. Pediatr Res 2000;47:830–3.
§Sources: Roe CR, Roe DS. Recent developments in the investigation of inherited metabolic
disorders using cultured human cells. Mol Genet Metab 1999;68:243–57; and Roe CR, Roe
DS. Detection of gene defects in branched-chain amino acid metabolism by tandem mass
spectrometry of carnitine esters produced by cultured fibroblasts. In: Harris RA, Sokatch JR,
eds. Methods in enzymology. Vol 324. San Diego, California: Academic Press, 2000:424–31.
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Tandem Mass Spectrometry in the New South Wales Newborn Screening Program
— Bridget Wilcken, M.B., Ch.B.; Veronica Wiley, Ph.D.; New Children’s Hospital,
Sydney, Australia
We introduced electrospray tandem mass spectrometry (MS/MS) into the New South
Wales newborn screening program in 1998.* We have screened 196,000 babies, usually
on day 3 of life. A total of 50 babies had confirmed defects, approximately the expected
rate based on 20 years’ previous experience in our statewide biochemical genetics
laboratory or on known mutation frequencies: phenylketonuria 28 (21 expected);
biopterin defects, two; other aminoacidopathies, five; organic aciduria disorder, three;
medium-chain acyl-CoA dehydrogenase deficiency, six (six expected); other fatty acid
oxidation disorders, two; noninborn errors (neonatal hepatitis or maternal B12 defi-
ciency), four. Three were known false-negatives, cases of nonketotic hyerglycinaemia,
tyrosinaemia type I, and cobalamin C defect. Only 210 repeat samples were requested
from babies not having a proven defect. The substantial number of primary analytes
used gives a risk for an unacceptable recall rate. Analysis of many retrospective new-
born samples from cases later diagnosed clinically is required. An experienced bio-
chemical genetics laboratory and quality-assurance programs are requirements for
diagnosis and later monitoring. Where the screening laboratory is not linked to a bio-
chemical genetics laboratory, record keeping will be more difficult because final diagno-
sis takes time, and the risk exists of recording cases that are really false-positives. Because
diagnosis of clinically nonsignificant conditions can be a problem where experienced
teams are not available, a limited number of specified disorders should be sought in the
first instance. Treatment of asymptomatic babies has not proven to be a problem and is
not different from the familiar phenylketonuria situation. Certain potentially detectable
disorders are extremely rare. Follow-up should be done only by a clinical biochemical
geneticist experienced in managing metabolic disorders, with multidisciplinary care,
expert dietician, and biochemical genetics laboratory support. Evaluation of cost-benefit
and reduction in morbidity and mortality will be extremely difficult unless accurate,
comprehensive records are available for the state or area. We have records of all rel-
evant inborn errors of metabolism detected in New South Wales over the last 20 years.
We will use historical controls to come to an estimate of benefit. Randomized controlled
trials for the most part will not be possible because of the rarity of individual conditions.
University of Wisconsin Biochemical Genetics Program — Jon Wolff, M.D.; Sandra
van Calcar, M.S.; Kristine K. Hanson, M.S.; University of Wisconsin, Madison,
Wisconsin
In June 1999, the University of Wisconsin Biochemical Genetics Program became
involved in the follow-up of abnormal acylcarnitine test results. Our team includes a
board-certified biochemical geneticist, a nutritionist, and a genetics counselor. The state
laboratory reports all abnormal test results to us and the physician of record. Immedi-
ately, our geneticist contacts the child’s physician to discuss the diagnosis and arrange
follow-up testing. For all disorders, follow-up testing includes urinary organic acids and
repeat acylcarnitines, which usually takes 1–2 weeks. During this time, the physician is
asked to watch for signs of metabolic crisis and instructed how to treat a patient having
*Source: Wiley V, Carpenter K, Wilcken B. Newborn screening with tandem mass-spectrometry:
12 months’ experience in NSW Australia. Acta Paediatr Suppl 1999:432:48–51.
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an acute episode (i.e., with intravenous fluids or glucose). The genetic counselor identi-
fies or creates resource materials for the physician and family and is available to the
family during this time. If an abnormal test result is confirmed by follow-up testing, the
child is examined and the parents provided nutrition consultation and genetic counseling.
Our patient treatment for confirmed short- and medium-chain acyl-CoA dehydrogenase
disorders includes four components,
• avoidance of fasting;
• administration of carnitine at 50 mg/kg/day, divided, 3 times/day;
• consumption of a moderately low-fat diet (e.g., 30% kcal from fat); and
• prompt treatment for vomiting episodes with intravenous fluids or glucose.
An emergency protocol is written for each child and given to parents for delivery to
emergency department personnel, if needed. Because increasing physician awareness
and creating resource materials for physicians and patients’ families is a high priority, we
are developing an education module for physicians.
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